Effective decoration of Pd nanoparticles on the surface of SnO2 nanowires for enhancement of CO gas-sensing performance.

Decoration of noble metal nanoparticles (NPs) on the surface of semiconducting metal oxide nanowires (NWs) to enhance material characteristics, functionalization, and sensing abilities has attracted increasing interests from researchers worldwide. In this study, we introduce an effective method for the decoration of Pd NPs on the surface of SnO2 NWs to enhance CO gas-sensing performance. Single-crystal SnO2 NWs were fabricated by chemical vapor deposition, whereas Pd NPs were decorated on the surface of SnO2 NWs by in situ reduction of the Pd complex at room temperature without using any linker or reduction agent excepting the copolymer P123. The materials were characterized by advanced techniques, such as high-resolution transmission electron microscopy, scanning transmission electron microscopy, and energy-dispersive X-ray spectroscopy. The Pd NPs were effectively decorated on the surface of SnO2 NWs. As an example, the CO sensing characteristics of SnO2 NWs decorated with Pd NPs were investigated at different temperatures. Results revealed that the gas sensor exhibited excellent sensing performance to CO at low concentration (1-25ppm) with ultrafast response-recovery time (in seconds), high responsivity, good stability, and reproducibility.

The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis.

BACKGROUND/AIM: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC. METHODS: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy. RESULTS: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab. CONCLUSIONS: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.